Published in NDT Plus on November 03, 2009
Prevalence of lysosomal storage disorders. JAMA (1999) 9.06
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest (2004) 4.54
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet (2001) 3.23
Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med (2003) 2.54
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID. J Biol Chem (1963) 2.24
Fabry disease in childhood. J Pediatr (2004) 2.20
A wild zebra chase. Nephrol Dial Transplant (2007) 1.60
Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab (2003) 1.44
Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat (2003) 1.42
Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis (2006) 0.99
Deficient alpha-galactosidase A activity in plasma but no Fabry disease--a pitfall in diagnosis. Clin Chem Lab Med (2005) 0.84
Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol (2004) 0.81